FDA Approves FOSAPREPITANT — Avenacy, LLC

Avenacy, LLC won FDA approval on Wednesday to sell the generic version of Fosaprepitant Dimeglumine, an IV anti-emetic used to prevent chemotherapy-induced nausea and vomiting, addressing a $360 million market specialty. This launch provides significant competitive relief to patients and the healthcare sector, potentially driving down drug prices for a critical therapy used before CINV-inducing chemotherapy regimens.